Assertive Community Treatment (ACT) as Part of Integrated Care Versus Standard Care: a 12-month Trial in Patients With First- and Negatively Selected Multiple-episode Schizophrenia-spectrum Disorders Treated With Quetiapine IR
The ACCESS trial, sponsored by Universitätsklinikum Hamburg-Eppendorf, investigates the effectiveness of Assertive Community Treatment (ACT) as part of integrated care compared to standard care in patients with schizophrenia spectrum disorders treated with quetiapine IR. Given the rising prevalence of schizophrenia and the need for effective treatment strategies, this study addresses a significant market opportunity. The findings could enhance the positioning of quetiapine IR in the competitive landscape, particularly against other antipsychotics and integrated care models. The results may also inform payers and healthcare providers regarding cost-effectiveness, potentially influencing reimbursement strategies and market access.
Indication: Schizophrenia
Modality: behavioral intervention
Target: Quetiapine Immediate Release (IR) as a treatment for schizophrenia spectrum disorders.
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Source URL: ClinicalTrials.gov
Source updated: Mar 05, 2010
Ingested: Jun 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Quetiapine Immediate Release (IR) as a treatment for schizophrenia spectrum disorders.
View original source fields
Condition raw: Schizophrenia
Condition normalized: Schizophrenia
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: Quetiapine Immediate Release (IR) as a treatment for schizophrenia spectrum disorders.
Target normalized: Quetiapine Immediate Release (IR) as a treatment for schizophrenia spectrum disorders.